A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy
Some chemotherapy and antibody drugs damage the heart. Checking heart function before and during treatment and starting protective drugs early for those at risk could prevent much of that damage.
Anthracyclines, HER2-targeted therapy, and some kinase inhibitors cause cardiac dysfunction that is often detected late. Guidelines (ESC 2022 cardio-oncology) recommend baseline risk assessment, biomarker and strain-imaging surveillance, and cardioprotective therapy for high-risk patients, but implementation is inconsistent and cardio-oncology clinics are rare outside academic centres. A pathway with automatic risk scoring at prescription, scheduled surveillance, and protocolised initiation of protective therapy would standardise this.
- Survivorship and late effects are neglected · Tens of millions of people live after cancer with heart damage, infertility, second cancers and fear, and few services.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
Pages like this
not linked directly; found by shared links- IdeaBiomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy
Shares Cardio-oncology, Survivorship and late effects are neglected, Trastuzumab, Toxicity and quality of life are undervalued.
- TermTrastuzumab cardiotoxicity
Shares Cardio-oncology, Survivorship and late effects are neglected, Trastuzumab, HER2-positive breast cancer.
- IdeaRisk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care
Shares Cardio-oncology, Survivorship and late effects are neglected.
- IdeaVocational rehabilitation integrated into cancer care so survivors can return to work
Shares Survivorship and late effects are neglected, Toxicity and quality of life are undervalued.
- IdeaMeasure and treat chemo brain with objective digital cognitive testing
Shares Survivorship and late effects are neglected, Toxicity and quality of life are undervalued.
- IdeaA survivor biobank to find who will develop late effects before they do
Shares Cardio-oncology, Survivorship and late effects are neglected.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Trastuzumab, HER2-positive breast cancer, Diffuse large B-cell lymphoma.
- IdeaProspective arm-volume surveillance to catch and reverse lymphoedema early
Shares Survivorship and late effects are neglected, Toxicity and quality of life are undervalued.